Julie Clark M.D., Adverum?s Chief Medical Officer (CMO), advised Adverum that she is resigning as an officer of Adverum stating personal reasons and a desire to focus on work-life balance.?Her resignation is effective October?22, 2021.?There were no disagreements, including on Adverum?s development programs or plans, between Dr.?Clark and the company. Adverum is engaged in a search for a new CMO and Laurent Fischer M.D., Adverum?s President and Chief Executive Officer, will serve as CMO in an interim basis. Dr.?Clark?s departure does not impact Adverum?s plans to proceed with a Phase 2 trial of ADVM-022 in wet age-related macular degeneration (wet AMD).